Meiji Yasuda Asset Management Co Ltd. Has $580,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Meiji Yasuda Asset Management Co Ltd. grew its position in Moderna, Inc. (NASDAQ:MRNA) by 6.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,887 shares of the company’s stock after purchasing an additional 287 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Moderna were worth $580,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Ontario Teachers Pension Plan Board acquired a new stake in Moderna during the 4th quarter worth $1,358,000. Hobbs Group Advisors LLC acquired a new stake in shares of Moderna during the fourth quarter worth about $664,000. Illinois Municipal Retirement Fund lifted its holdings in shares of Moderna by 22.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock valued at $5,519,000 after purchasing an additional 9,360 shares in the last quarter. Swedbank AB acquired a new position in shares of Moderna in the 1st quarter valued at approximately $3,315,000. Finally, Wellington Management Group LLP increased its stake in Moderna by 28.8% during the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after purchasing an additional 1,614,460 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of MRNA stock opened at $65.69 on Friday. The company has a fifty day moving average price of $90.07 and a two-hundred day moving average price of $110.76. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The stock has a market cap of $25.18 billion, a P/E ratio of -4.19 and a beta of 1.68. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s revenue was down 29.9% on a year-over-year basis. During the same period last year, the business posted ($3.62) EPS. As a group, equities analysts predict that Moderna, Inc. will post -9.52 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Evercore ISI reaffirmed an “in-line” rating and issued a $120.00 target price on shares of Moderna in a research note on Thursday, June 27th. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. TD Cowen reduced their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Finally, Leerink Partners dropped their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $100.44.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total value of $1,908,300.00. Following the sale, the director now owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30. The disclosure for this sale can be found here. In the last three months, insiders sold 93,158 shares of company stock worth $11,167,312. 15.70% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.